摘要
神经母细胞瘤(NB)是儿童期最常见的颅外实体瘤,异质性是NB的主要特征:临床表现多样,涉及多个学科;分子特征及组织学类型个体差异大,预后转归或自然退化,或迅猛进展。治疗选择需依据危险度分级,其中高危组是治疗难点。治疗过程分为诱导、巩固及维持治疗3阶段。随着单细胞研究及精准测序的引入,NB未来会进入免疫靶向治疗时代。
Neuroblastoma is the most common extracranial solid tumor in childhood. Heterogeneity is the main feature of NB with diverse clinical presentations,various molecular-pathology,and vastly contrasting prognosis. Treatment selection must be based on risk grade. The therapy for high-risk disease is the focus,which includes three phases：induction,consolidation,and maintenance. With the introduction of single cell technology and precise sequencing,NB will enter the era of molecular targeting and immunotherapy.
作者
王景福
WANG Jing-fu(Department of Pediatric Oncology,Tianjin Medical University Cancer Hos-pital,Tianjin 300060,China)
出处
《中国实用儿科杂志》
CSCD
北大核心
2018年第10期763-768,共6页
Chinese Journal of Practical Pediatrics
